Centogene BV: Analysts say "unmatched database", start coverage with "buy"

Crown LiquidationCo NV in liquidatie

02/12/2019 12:30

** Evercore ISI starts coverage on drugmaker  CNTG.O  with
"outperform" rating and PT of $17
    ** Analyst Luke Sergott views CNTG's rare diseases database
to be worth ~$2 bln; expects rev. growth of ~30% over the next 3
years
    ** Brokerage says CNTG's database is unmatched in its space,
even when compared to the consolidated database of its
competitors 
    ** Brokerage BTIG starts coverage with "buy" rating and PT
of $18
    ** CNTG has a robust growth momentum and has unique
capabilities to address significant unmet needs in rare disease
diagnostics and therapeutics development - BTIG
    ** BTIG expects biopharma partnerships to be the biggest
value creators for CNTG going forward
    ** CNTG's stock had gained 3.85% as of Friday, since its
debut in Nov

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 7786;))